
Sponsorship: Supported by SIDACTION, the Agence Nationale de Recherches sur le SIDA (ANRS), ECOS-CONICYT and FONDCTY de Chile (project no. 1940570).


References


HIV-1 group O virus infection in Abidjan, Côte d'Ivoire

Côte d'Ivoire is the West African country that is most severely affected by the AIDS epidemic. In Abidjan, the economic capital, 15% of pregnant women and 45% of tuberculosis patients are HIV-infected [1,2]. Surveillance of HIV-1 subtypes among tuberculosis patients reveals that more than 90% of HIV-1 infections are due to subtype A; among persons with HIV-2 infection, HIV-2 subtypes A and B predominate [3].

The highly divergent HIV-1 group O virus, first identified in Cameroon in 1990 [4,5], is of public health interest because infections with this strain of viruses are not uniformly detected by some commercial serological assays [6,7]. To date, no formal surveillance for HIV-1 group O infections has been carried out in Abidjan. To elaborate and validate HIV serological algorithms in this population severely affected by the AIDS epidemic, we need a better understanding of the prevalence of this infection.

A total of 4451 serum or plasma samples obtained from various populations in Abidjan were selected for testing. All the samples had been tested previously by at least one whole virus lysate enzyme-linked immunosorbent assay (ELISA; HIV-1 and HIV-2, Genetic Systems, Seattle, Washington, USA; or Genelavia Mixt, Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France). These assays have been shown to have high sensitivity for the detection of antibodies to HIV-1 group O viruses [6,8]. The serostatus for the samples that were ELISA-positive was defined either by Western blot testing (HIV-1 Western blot, Genelabs Diagnostic, Singapore; HIV-2 Western blot, Sanofi Diagnostics Pasteur) or Peptilav 1-2 (Sanofi Diagnostics Pasteur) or Peptilav 1-2 (Sanofi Diagnostics Pasteur) or Peptilav 1-2 (Sanofi Diagnostics Pasteur). Samples were collected between 1994 and 1997 from participants in epidemiological studies: 1396 female sex workers (1240 HIV-seropositive, 151 HIV-sonergative, five Western blot-indeterminate), 712 pregnant women (604 HIV-seropositive, eight HIV-seronegative, 100 indeterminate), 1011 HIV-positive hospitalized patients, 1011 tuberculosis patients (975 HIV-seropositive, 12 HIV-sonergative, 24 indeterminate), and 321 blood donors (31 HIV-seropositive, 290 HIV-sonergative). Of the 4451 samples, 3228 were typed as HIV-1, 24 as HIV-2, and 578 as HIV-1 and HIV-2 dually reactive; 31 other sera from blood donors were HIV-seropositive, but information was not available for HIV type; 129 sera were Western blot-indeterminate; and 461 sera were HIV-sonergative by standard testing.
To detect antibody to HIV-1 group O, we tested all sera by a research ELISA (Innogenetic, Ghent, Belgium) that incorporated a combination of V3-loop peptides from the ANT70 and MVP-5180 HIV-1 group O isolates [9,10]. Sera reactive by this ELISA were further tested by a group O-specific line immunoassay (LIA-O, Innogenetic), in which biotinylated V3 peptides from different group O and group M HIV-1 viruses were applied as a streptavidin complex in parallel lines on nylon strips. All samples that were either reactive (reactivity to group O V3-loop peptide) or indeterminate (reactivity both to group M and O V3-loop peptides) in LIA were further analysed using an HIV-1 reverse transcriptase (RT) PCR assay, by using primers sensitive and specific for group O viruses [10,11].

Of the 4451 samples, 37 (0.8%) were reactive by the group O-specific ELISA. When tested by LIA-O, 19 were indeterminate and 18 were negative. The 19 indeterminate samples were further tested by RT-PCR, but only one was positive. Thus, the overall prevalence of confirmed group O infection was one (0.02%) for all 4451 sera, or one (0.03%) out of all the 3861 HIV-seropositive sera. The confirmed HIV-1 group O sample was obtained in 1996 from a 22-year-old HIV-1-seropositive Ivorian woman hospitalized for meningitis. It is possible that some of the LIA-O-indeterminate samples were falsely negative by RT-PCR because of poor specimen storage conditions. However, it is more likely that these samples represent HIV group M infections. Peeters et al. [10] found that most samples that cross-reacted simultaneously with group O and M peptides in LIA-O were infected only with HIV-1 group M viruses.

Our finding of a very low (0.03%) prevalence of group O viruses in persons infected with HIV is in accordance with studies that have reported low prevalence of group O infections in West African countries, including Senegal (0.07%), Togo (0.14%), Niger (0.3%), Mali (0%), and Burkina Faso (0%) [9,10]. These findings suggest that the current HIV serological algorithm used in Abidjan is suitable. However, periodic surveillance for divergent HIV strains is important because of the high prevalence of HIV and the great mobility of the local population.

Acknowledgements
The authors thank D. Yavo, C. Bile, E. Boateng, C. Nambaté, and M.-Y. Borget for technical assistance, P. Ghys for providing sera from female sex workers, and P. Pinay for providing sera from blood donors.


Date of receipt: 18 March 1998; accepted: 24 March 1998.

References
1405 Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing
J.N. Nkengasong, B. Willems, W. Janssens, R. Cheingsong-Papov, L. Heyndrickx, F. Borin, P. Czerbo, K. Fransen, J. Goodhew and G. van der Groen

1413 Structure-based design of peptides that recognize the CD4 binding domain of HN-1 gp120
J.O. Fontenot, X. Ton and D.M. Phillips

1419 Improved detection of HN-2 proviral DNA in dually seroreactive individuals by PCR

1427 Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1 disease
A-M. Canoe, K. Tarte, J. Remes, M. Secondi

1437 Rate of HN-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen

1447 Kaposi's sarcoma in HN infection: impact on opportunistic infections and survival
H.B. Brand, B.S. Kampa, E.B. Hein, H. Schiller and P. Mirou

1451 Mycobacterium tuberculosis infection and disease in HIV-seropositive women receiving highly active antiretroviral therapy
I. Heard, V. Schwitz, D. Costagliola, G. Orth and M.D. Kalaszinska

1459 Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy
M. Bode, R.D. Moare, N.M.H. Graham, J. Aslembarski, D. Vlahov and R.E. Chairson

1459 The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis
J.C.M. Hendriks, G.A. Satten, E.J.C. van Ameijden, H.A.M. van Drul, R.A. Coutinho and G.J.P. van Griensven

1475 Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants

1483 Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen

1503 Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis
A.M. Bayoumi and D.A. Redelmeier

1521 Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand
V. Chudbonchat, T.B. Mass, W. Sirawarat, B. Sutharaks, F. Suthathai, F.K. Nossom, V. Vacharak, J. Grimes, G. Theofan and D.J. Cark

1537 The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis
J.C.M. Hendriks, G.A. Satten, E.J.C. van Ameijden, H.A.M. van Drul, R.A. Coutinho and G.J.P. van Griensven

1549 Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants

CORRESPONDENCE
Meetings • Guidance for authors • Fast Track submission form